CVS Warns Broader Cost Controls Coming As Economic Downturn Collides With Costly New Therapies
CVS Caremark's Lotvin reports increased US payer interest in more comprehensive drug management solutions and that some payers are asking about dropping coverage for drug categories.
You may also be interested in...
Payer concessions to ensure access to drugs during the COVID-19 outbreak offer a benefit to patients and biopharma. But the costs involved could intensify future efforts to manage drug spending.
Germany uses government facilitated price negotiations between publicly funded insurers and manufacturers that are based on an independent assessment of how much added value a drug provides.
Teva, Sun and the AAM are among those urging the CMS to rescind its proposal to reimburse Part B drugs approved under section 505(b)(2) as multiple source products. The proposal would target one relatively small but growing part of Medicare Rx spending and reflects CMS’ ongoing concern with fast rising costs in the program.